4.6 Article

Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Immunology

Decreased Susceptibility to Dihydrofolate Reductase Inhibitors Associated With Genetic Polymorphisms in Ugandan Plasmodium falciparum Isolates

Oriana Kreutzfeld et al.

Summary: This study investigated the susceptibility of P falciparum field isolates to PfDHFR inhibitors in two districts of Uganda and found common resistance-mediating mutations in Uganda. However, the new compound P218 retained excellent activity against mutant parasites.

JOURNAL OF INFECTIOUS DISEASES (2022)

Article Multidisciplinary Sciences

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183

Laura E. de Vries et al.

Summary: In this study, a pantothenamide, MMV693183, was presented as a first-in-class acetyl-CoA synthetase (AcAS) inhibitor with attractive drug-like properties and in vivo efficacy. The compound showed potent activity against Plasmodium falciparum and Plasmodium vivax, and effectively blocked transmission to Anopheles mosquitoes. These findings make MMV693183 a promising candidate for further clinical development.

NATURE COMMUNICATIONS (2022)

Article Chemistry, Medicinal

Pre-erythrocytic Activity of M5717 in Monotherapy and Combination in Preclinical Plasmodium Infection Models

Diana Fontinha et al.

Summary: Combination therapy is effective in reducing drug resistance in malaria. The combination of M5717 and pyronaridine shows potent activity against blood stage Plasmodium infection. Additionally, pyronaridine enhances the activity of M5717 against hepatic infection. These findings support the clinical evaluation of pyronaridine as a partner drug for M5717.

ACS INFECTIOUS DISEASES (2022)

Article Microbiology

Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors

Shreeya Garg et al.

Summary: This study assessed the drug resistance and genetic variation of proteasome inhibitors against Plasmodium falciparum isolates in Uganda. The results showed that proteasome inhibitors had potent activity against circulating P. falciparum isolates in Uganda, with little genetic variation in the proteasome targets.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Article Multidisciplinary Sciences

Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda

Patrick K. Tumwebaze et al.

Summary: This study found that the partial resistance to artemisinin may lead to the selection of Plasmodium falciparum that is resistant to combination therapy partner drugs. The susceptibility to lumefantrine and dihydroartemisinin was lower in northern Uganda where resistance-associated mutations have emerged, compared to eastern Uganda. Multiple genetic polymorphisms were associated with altered drug susceptibility in Plasmodium falciparum.

NATURE COMMUNICATIONS (2022)

Article Chemistry, Medicinal

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362

Martin A. . Lowe et al.

Summary: This study optimized Plasmepsin X (PMX) and identified potent PMX inhibitors with potential efficacy in treating malaria.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Biochemistry & Molecular Biology

The Plasmodium falciparum ABC transporter ABCI3 confers parasite strain-dependent pleiotropic antimalarial drug resistance

James M. Murithi et al.

Summary: This study identifies the transporter ABCI3 and the chloroquine resistance transporter PfCRT as key players in drug resistance in Plasmodium falciparum. The mode of action of the compound imidazopyridine is attributed to inhibition of heme detoxification.

CELL CHEMICAL BIOLOGY (2022)

Article Biochemistry & Molecular Biology

Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention

Robert L. Summers et al.

Summary: In this study, we identified and validated the Plasmodium falciparum acetyl-coenzyme A synthetase (PfAcAS) as an important, druggable target. Genetic and chemical validation confirmed that mutations in PfAcAS confer resistance to two antiplasmodial compounds and that these compounds directly inhibit the enzyme. We also found that PfAcAS is essential for asexual growth and involved in the epigenetic regulation of gene expression.

CELL CHEMICAL BIOLOGY (2022)

Article Multidisciplinary Sciences

Structural basis of malaria parasite phenylalanine tRNA-synthetase inhibition by bicyclic azetidines

Manmohan Sharma et al.

Summary: The novel series of bicyclic azetidines has shown potential in inhibiting Plasmodium cytosolic phenylalanine tRNA-synthetase (cFRS) and could serve as competitive inhibitors of L-Phe, providing a structural framework for drug development against both Plasmodium and related apicomplexans. The co-crystal structure of a PvcFRS-BRD1389 complex reveals how the bicyclic azetidine ligand binds to distinct subsites within the PvcFRS catalytic site, offering insights into its mechanism of action.

NATURE COMMUNICATIONS (2021)

Article Chemistry, Medicinal

Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series

Michael J. Palmer et al.

Summary: DHODH has been clinically validated as a target for new antimalarials, and a structure-based computationally driven lead optimization program of DHODH inhibitors has led to the discovery of two promising candidates for potential advancement to preclinical development. These compounds exhibit improved physicochemical properties, potent antimalarial activity in vitro, and good efficacy in Plasmodium falciparum SCID mouse models, showing selectivity for Plasmodium DHODHs versus mammalian enzymes.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Infectious Diseases

Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study

Aline Uwimana et al.

Summary: This study confirms the emergence of artemisinin partial resistance in Rwanda. Although artemether-lumefantrine remains efficacious, vigilance for decreasing efficacy and further characterization of artemisinin partial resistance should be considered. Evaluation of additional antimalarials in Rwanda is also recommended.

LANCET INFECTIOUS DISEASES (2021)

Review Infectious Diseases

Artemisinin and multidrug-resistant Plasmodium falciparum - a threat for malaria control and elimination

Mehul Dhorda et al.

Summary: Artemisinin-resistant Plasmodium falciparum has emerged in various regions, leading to significant ACT treatment failures. Aggressive malaria elimination programs in the Greater Mekong Subregion have been successful in preventing the spread of resistance, but mutations in the pfk13 gene have appeared in other parts of Asia, Africa, and South America. Enhanced surveillance and treatment strategies are necessary to address emerging resistance and prevent multidrug resistance.

CURRENT OPINION IN INFECTIOUS DISEASES (2021)

Article Medicine, General & Internal

Evidence of Artemisinin-Resistant Malaria in Africa

Betty Balikagala et al.

Summary: Research conducted in Northern Uganda revealed the emergence of artemisinin-resistant Plasmodium falciparum strains, with predominant mutations found in the kelch13 gene. Thirteen patients were infected with P. falciparum parasites carrying mutations in the A675V or C469Y allele, which were associated with prolonged parasite clearance half-lives.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Immunology

Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda

Victor Asua et al.

Summary: This study identified concerning spread of mutations that may limit the efficacies of key antimalarial drugs in multiple sites in Uganda.

JOURNAL OF INFECTIOUS DISEASES (2021)

Article Chemistry, Medicinal

Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria

Sreekanth Kokkonda et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Article Multidisciplinary Sciences

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

Beatriz Baragana et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Article Pharmacology & Pharmacy

Increased stress associated with head-out plethysmography testing can exacerbate respiratory effects and lead to mortality in rats

James J. Lynch et al.

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2019)

Article Cell Biology

Antimalarial pantothenamide metabolites target acetyl-coenzyme A biosynthesis in Plasmodium falciparum

Joost Schalkwijk et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Article Pharmacology & Pharmacy

The antimalarial pipeline

Rob Hooft van Huijsduijnen et al.

CURRENT OPINION IN PHARMACOLOGY (2018)

Editorial Material Medicine, Research & Experimental

How to tackle antimalarial resistance?

Didier Leroy

EMBO MOLECULAR MEDICINE (2017)

Article Chemistry, Multidisciplinary

Synthesis of a Bicyclic Azetidine with In Vivo Antimalarial Activity Enabled by Stereospecific, Directed C(sp3)-H Arylation

Micah Maetani et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)

Review Infectious Diseases

New developments in anti-malarial target candidate and product profiles

Jeremy N. Burrows et al.

MALARIA JOURNAL (2017)

Article Chemistry, Medicinal

Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit P-falciparum Dihydroorotate Dehydrogenase

Micah Maetani et al.

ACS MEDICINAL CHEMISTRY LETTERS (2017)

Article Multidisciplinary Sciences

Esterase mutation is a mechanism of resistance to antimalarial compounds

Eva S. Istvan et al.

NATURE COMMUNICATIONS (2017)

Article Chemistry, Multidisciplinary

Production of New Cladosporin Analogues by Reconstitution of the Polyketide Synthases Responsible for the Biosynthesis of this Antimalarial Agent

Rachel V. K. Cochrane et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)

Article Microbiology

Antimalarial Benzoxaboroles Target Plasmodium falciparum Leucyl-tRNA Synthetase

Ebere Sonoiki et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Article Multidisciplinary Sciences

Diversity-oriented synthesis yields novel multistage antimalarial inhibitors

Nobutaka Kato et al.

NATURE (2016)

Article Multidisciplinary Sciences

A novel multiple-stage antimalarial agent that inhibits protein synthesis

Beatriz Baragana et al.

NATURE (2015)

Review Biotechnology & Applied Microbiology

Malaria medicines: a glass half full?

Timothy N. C. Wells et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

Article Multidisciplinary Sciences

Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1

Michael J. Capper et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)

Article Cell Biology

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Margaret A. Phillips et al.

SCIENCE TRANSLATIONAL MEDICINE (2015)

Article Multidisciplinary Sciences

Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate

Shahul P. Hameed et al.

NATURE COMMUNICATIONS (2015)

Review Microbiology

Key molecular events during host cell invasion by Apicomplexan pathogens

Pushkar Sharma et al.

CURRENT OPINION IN MICROBIOLOGY (2013)

Article Biochemistry & Molecular Biology

Kinetic Flux Profiling Elucidates Two Independent Acetyl-CoA Biosynthetic Pathways in Plasmodium falciparum

Simon A. Cobbold et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2013)

Article Cell Biology

Quinolone-3-Diarylethers: A New Class of Antimalarial Drug

Aaron Nilsen et al.

SCIENCE TRANSLATIONAL MEDICINE (2013)

Review Parasitology

The ABCs of multidrug resistance in malaria

Jan B. Koenderink et al.

TRENDS IN PARASITOLOGY (2010)

Article Biochemistry & Molecular Biology

Acidification of the malaria parasite's digestive vacuole by a H+-ATPase and a H+-pyrophosphatase

KJ Saliba et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2003)